▶ SURVODUTIDE · SUBTOPIC · SAFETY PROFILE

SURVODUTIDE Safety Profile

For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of SURVODUTIDE.

OBSERVED ADVERSE EVENTS IN LITERATURE

The following adverse events have been observed in trials or animal studies of SURVODUTIDE. Severity, frequency, and attribution depend on the source publication.

GI: nausea, vomiting, diarrhea
Injection-site reactions
Tachycardia (modest)

DRUG INTERACTIONS

The following interactions are reported in or theorised from the published mechanism for SURVODUTIDE.

Glucagonergic effects may interact with sulfonylureas/insulin

CONTRAINDICATIONS REPORTED IN LITERATURE

Contraindications recorded for SURVODUTIDE in the published record:

History of MTC or MEN2

FDA REGULATORY STATUS

Investigational. Phase 3 SYNCHRONIZE-1/2 obesity trials enrolling.

WADA REGULATORY STATUS

Not currently listed on the WADA Prohibited List.

SAFETY Q+A FROM LITERATURE

▶ Is survodutide FDA-approved?

Not yet as of 2026-05. Phase 3 SYNCHRONIZE-1 and SYNCHRONIZE-2 trials for obesity are enrolling.

CITED LITERATURE

The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.

Le Roux CW, et al.. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol 2024. PMID 38219768. link
Boehringer Ingelheim. A study of survodutide in adults with overweight or obesity (SYNCHRONIZE-1). ClinicalTrials.gov · Phase 3 2024. NCT06066515. link

◀ SURVODUTIDE OVERVIEW MECHANISM ▶DOSING LITERATURE ▶

▶ LAST UPDATED · 2026-05-19